ID
34001
Description
Study ID: 102936 Clinical Study ID: HZA102936 Study Title:A randomised, placebo-controlled, four-way crossover repeat dose study to evaluate the effect of the inhaled fluticasone furoate (FF)/GW642444M combination on electrocardiographic parameters, with moxifloxacin as a positive control, in healthy subjects Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT01209026 https://clinicaltrials.gov/ct2/show/NCT01209026?term=NCT01209026 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 1 Study Recruitment Status: Completed Generic Name: fluticasone furoate Trade Name: Allermist,Veramyst,Avamys; Veramyst,Avamys,Allermist Study Indication: Asthma The study consists of a screening, 4 treatment periods and a follow up. Treatment periods 1-4 are each 7 days long. Treatment period 1 Days 1-6 (TP1D-D6) Treatment period 1 Day 7 (TP1D7) Treatment period 2 Days 1-6 (TP2D1-D6) Treatment period 2 Day 7 (TP2D7) Treatment period 3 Days 1-6 (TP3D1-D6) Treatment period 3 Day 7 (TP3D7) Treatment period 4 Days 1-6 (TP4D1-D6) Treatment period 4 Day 7 (TP4D7) This document contains the Pharmacogenetic (PGx) research withdrawl of consent (PGx withdrawl) form. It has to be filled in for the end of study.
Lien
https://clinicaltrials.gov/ct2/show/NCT01209026?term=NCT01209026
Mots-clés
Versions (3)
- 08/01/2019 08/01/2019 -
- 10/01/2019 10/01/2019 - Sarah Riepenhausen
- 10/01/2019 10/01/2019 - Sarah Riepenhausen
Détendeur de droits
GlaxoSmithKline
Téléchargé le
10 janvier 2019
DOI
Pour une demande vous connecter.
Licence
Creative Commons BY-NC 3.0
Modèle Commentaires :
Ici, vous pouvez faire des commentaires sur le modèle. À partir des bulles de texte, vous pouvez laisser des commentaires spécifiques sur les groupes Item et les Item.
Groupe Item commentaires pour :
Item commentaires pour :
Vous devez être connecté pour pouvoir télécharger des formulaires. Veuillez vous connecter ou s’inscrire gratuitement.
Effect of inhaled fluticasone furoate/Vilanterol combination on electrocardiographic parameters in healthy subjects, NCT01209026
Pharmacogenetic (PGx) research withdrawl of consent (PGx withdrawl)
Description
Pharmacogenetic (PGx) research withdrawl of consent
Alias
- UMLS CUI-1
- C2347500
- UMLS CUI-2
- C1707492
Description
Withdrawl of consent for PGx
Type de données
text
Alias
- UMLS CUI [1,1]
- C1707492
- UMLS CUI [1,2]
- C2347500
Description
day month year
Type de données
date
Alias
- UMLS CUI [1,1]
- C1707492
- UMLS CUI [1,2]
- C2347500
- UMLS CUI [1,3]
- C0011008
Description
Request to sample destruction
Type de données
text
Alias
- UMLS CUI [1,1]
- C1948029
- UMLS CUI [1,2]
- C0178913
- UMLS CUI [1,3]
- C1272683
Description
Screen failure is an optional choice.
Type de données
text
Alias
- UMLS CUI [1,1]
- C1948029
- UMLS CUI [1,2]
- C0178913
- UMLS CUI [1,3]
- C1272683
- UMLS CUI [1,4]
- C0392360
Description
Other reason for request to sample destruction
Type de données
text
Alias
- UMLS CUI [1,1]
- C1948029
- UMLS CUI [1,2]
- C0178913
- UMLS CUI [1,3]
- C1272683
- UMLS CUI [1,4]
- C0392360
- UMLS CUI [1,5]
- C0205394
Similar models
Pharmacogenetic (PGx) research withdrawl of consent (PGx withdrawl)
C1707492 (UMLS CUI-2)
C2347500 (UMLS CUI [1,2])
C2347500 (UMLS CUI [1,2])
C0011008 (UMLS CUI [1,3])
C0178913 (UMLS CUI [1,2])
C1272683 (UMLS CUI [1,3])
C0178913 (UMLS CUI [1,2])
C1272683 (UMLS CUI [1,3])
C0392360 (UMLS CUI [1,4])
C0178913 (UMLS CUI [1,2])
C1272683 (UMLS CUI [1,3])
C0392360 (UMLS CUI [1,4])
C0205394 (UMLS CUI [1,5])